Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Conditions
Interventions
Brivanib
Brivanib Placebo
+1 more
Locations
94
United States
Richard Finn, M.D.
Los Angeles, California, United States
Sharp Clinical Oncology Research
San Diego, California, United States
Montefiore Medical Center
The Bronx, New York, United States
Rhode Island Hospital
Providence, Rhode Island, United States
The University Of Texas MD Anderson Cancer Center
Houston, Texas, United States
University Of Virginia Health System
Charlottesville, Virginia, United States
Start Date
July 20, 2009
Primary Completion Date
September 28, 2012
Completion Date
January 26, 2018
Last Updated
December 2, 2019
NCT06345508
NCT06811116
NCT07485114
NCT06066138
NCT04380545
NCT07291076
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions